Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone

European Neuropsychopharmacology

Volumn 12, Issue 4, 2002, Pages 305-310

  Peuskens, J ^a   Moller H J ^b   Puech, A ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF MUNICH   (Germany)

^c SANOFI   (France)

Author keywords

Affective symptoms; Amisulpride; Atypical antipsychotics; Schizophrenia

Indexed keywords

AMISULPRIDE; HALOPERIDOL; RISPERIDONE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ALEXITHYMIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; ADULT; BRIEF PSYCHIATRIC RATING SCALE; COMPARATIVE STUDY; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; COMPARATIVE STUDY; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMAN; MALE; MIDDLE AGE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0036019858     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00031-7     Document Type: Article

References (39)

1. Long-term treatment of mood disorders in schizophrenia
2. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis
3. Treatment of negative symptoms in schizophrenia with amisulpride
4. Amisulpride versus amineptine and placebo for the treatment of dysthymia
5. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study
6. Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses
7. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders
8. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
9. Safety of amisulpride (Solian): a review of 11 clinical studies
10. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
11. The causality of depression in schizophrenia
12. Depression in schizophrenia: are neuroleptics akinesia, or anhedonia involved?
13. The dysphoric syndrome in schizophrenia and its implications for relapse
14. The significance of depression in the prediction of relapse in chronic schizophrenia
15. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes
16. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group
17. Treatment of schizoaffective disorder and schizophrenia with mood symptoms
18. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
19. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol
20. The brief psychiatric rating scale
21. Antidepressant-like activity of amisulpride in two animal models of depression
22. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
23. Effects of risperidone on affective symptoms in patients with schizophrenia
24. Structure factorielle de l'échelle abrégée d'évaluation psychiatrique (BPRS)
25. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol
26. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators
27. Depression in chronic schizophrenia
28. Pharmacological treatment of schizophrenia
29. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV
30. Depression and schizophrenia
31. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study
32. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol
33. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
34. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
35. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol
36. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia
37. Akinetic depression in schizophrenia
38. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology-a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist